Key result
This review summarizes the latest developments in stroke prevention for atrial fibrillation, focusing on the choice between vitamin K antagonists and NOACs for patients with non-valvular AF.
This review summarizes the latest developments in stroke prevention for atrial fibrillation to assist physicians in choosing appropriate oral anticoagulants based on patient risk profiles.
Ischaemic strokes resulting from atrial fibrillation (AF) constitute a devastating condition for patients and their carers with huge burden on health care systems. Prophylactic treatment against systemic embolization and ischaemic strokes is the cornerstone for the management of AF. Effective stroke prevention requires the use of the vitamin K antagonists or non-vitamin K oral anticoagulants (NOACs). This article summarises the latest developments in the field of stroke prevention in AF and aims to assist physicians with the choice of oral anticoagulant for patients with non-valvular AF with different risk factor profile.
No takes yet. Share an insight, caveat, or question.
Voukalis et al. (2016) conducted a review in Atrial Fibrillation. Oral anticoagulants (vitamin K antagonists or NOACs) was evaluated. This review summarizes the latest developments in stroke prevention for atrial fibrillation, focusing on the choice between vitamin K antagonists and NOACs for patients with non-valvular AF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: